IMPT-514 is a bispecific CD19/CD20-targeting chimeric antigen receptor T-cell therapy. The Food and Drug Administration (FDA) has granted Fast Track designation to IMPT-514, a bispecific ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback